DALLAS, June 21, 2011 (GLOBE NEWSWIRE) -- MicroStockProfit.com announces an investment report featuring Acura Pharmaceuticals Inc. (Nasdaq:ACUR), highlighting the Company's recent U.S. Food and Drug Administration news, its most recent earnings figures, as well as comparative information you need to know to make an educated investment decision.
The full report is available at:
Acura Pharmaceuticals Inc. (ACUR) is a specialty pharmaceutical company engaged in research, development and commercialization of product candidates intended to potentially deter abuse and misuse utilizing its proprietary Aversion and Impede technologies. Its portfolio of product candidates includes opioid analgesics to relieve pain while simultaneously discouraging common methods of pharmaceutical product misuse and abuse, including intravenous injection of dissolved tablets or capsules; nasal snorting of crushed tablets or capsules, and intentional swallowing of excess quantities of tablets or capsules.
This newsletter has been helping traders make great investment decisions on ACUR; click here for a 25% discount offer.
In the report, the analyst notes:
"ACUR soared to a new 52-week high of $6.80 on Monday after the specialty pharmaceutical company announced that the Food and Drug Administration had approved a pain treatment co-developed by the Company and Pfizer Inc."
"We are excited to be partnered with Pfizer to bring Oxecta to patients who need opioids to manage their pain," ACUR interim president and CEO Robert Jones said. "Acura is focused on developing technologies that are intended to potentially deter abuse and misuse."
To read the entire report visit:
See what investors are saying about ACUR at
Get breaking news on ACUR at
MicroStockProfit.com is a small-cap research and investment commentary provider. MicroStockProfit.com strives to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on MicroStockProfit please visit:
MicroStockProfit.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. MicroStockProfit.com is a Web site wholly owned by BlueWave Advisors, LLC. Neither MicroStockProfit.com nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. Please read our report and visit our Web site, MicroStockProfit.com, for complete risks and disclosures.
CONTACT: Jay Geller email@example.com 1-888-307-2850